Opendata, web and dolomites

NANOBreg SIGNED

A new therapeutic platform based on nanotechnology to promote T- and B-regulatory networks

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NANOBreg project word cloud

Explore the words cloud of the NANOBreg project. It provides you a very rough idea of what is the project "NANOBreg" about.

pancreatic    recruitment    play    mhc    academic    diabetic    expanding    device    peripheral    santamaria    multidisciplinary    enterprise    inhibit    normoglycemia    mice    shown    bridging    huge    career    therapy    restore    t1d    autoantigenic    immunity    systemic    selectively    biology    nodes    human    functions    engrafted    complexity    np    magnetic    coated    recruited    industry    nsg    significance    loaded    lymph    cells    specificities    nanoparticles    area    immune    patients    humanized    enriched    strategies    manner    class    cell    complexes    animals    nanobreg    conversion    pmhc    roles    bottleneck    impairing    al    purge    barrier    diabetogenic    hypotheses    autoimmune    interaction    compounds    et    collectively    separation    cognate    peptide    critical    antigen    therapeutic    vivo    breg    presenting    cytokines    onset    blood    differentiation    diabetes    epitope    autoreactive    mononuclear    suppressing    nps    action    regulatory    cd4    autoreactivity    tr1    blunting    manufacturing    insights    plns    scalable    sepmag    translational    autoantigen    mechanisms    clinical   

Project "NANOBreg" data sheet

The following table provides information about the project.

Coordinator
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER 

Organization address
address: CALLE ROSSELLO 149 PUERTA BJS
city: BARCELONA
postcode: 8036
website: http://www.idibaps.org/en_index.html

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.idibaps.org
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2016
 Duration (year-month-day) from 2016-05-01   to  2018-05-13

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) coordinator 158˙121.00

Map

 Project objective

The complexity of autoimmune responses is a barrier to the design of strategies that can selectively purge the immune system of autoreactivity without impairing systemic immunity. Recently, Santamaria et al. have shown that nanoparticles (NPs) coated with type 1 diabetes (T1D)-relevant peptide–MHC (pMHC) complexes can restore normoglycemia in diabetic animals by blunting the diabetogenic autoimmune response without impairing systemic immunity. pMHC class II-NP therapy functions by expanding, in an epitope-specific manner, autoantigen-experienced T-regulatory-1 (TR1) CD4 T-cells that inhibit the recruitment of other autoantigenic specificities by: (1) suppressing autoantigen-loaded antigen-presenting cells in the pancreatic lymph nodes (PLNs); and (2) promoting the differentiation of B-cells into B-regulatory cells. Importantly, they have shown that human T1D-relevant pMHC class II-NPs also promote human TR1 CD4 T-cell formation in NSG mice engrafted with peripheral blood mononuclear cells from recent onset T1D patients.

Here, I propose a multidisciplinary approach to test the following hypotheses: (1) Breg formation is driven by a cognate interaction between TR1 cells and autoreactive B-cells; (2) TR1-derived cytokines play critical roles in TR1-driven Breg conversion in vivo; and (3) the B-cells that are recruited to the PLNs of pMHC-NP-treated humanized NSG mice are enriched for Breg cells. Furthermore, I will work with the enterprise SEPMAG, to design a scalable magnetic separation device for future clinical development of these compounds.

Collectively, NANOBreg will provide new insights into the biology of the TR1-Breg regulatory pathway and will enhance our knowledge on the mechanisms of action of this novel therapeutic approach. In addition, it will address a manufacturing bottleneck by bridging academic research with the manufacturing industry while enhancing my career development in an area of huge potential growth and translational significance.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANOBREG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANOBREG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

INFANTPATTERNS (2019)

Development of kinematic and muscle patterns in preterm infants

Read More